1. Home
  2. PNI vs ICCC Comparison

PNI vs ICCC Comparison

Compare PNI & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco New York Municipal Income Fund II of Beneficial Interest

PNI

Pimco New York Municipal Income Fund II of Beneficial Interest

HOLD

Current Price

$6.96

Market Cap

79.1M

Sector

Finance

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$7.50

Market Cap

64.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNI
ICCC
Founded
2002
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.1M
64.0M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
PNI
ICCC
Price
$6.96
$7.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
40.8K
20.3K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
4.76%
N/A
EPS Growth
N/A
53.85
EPS
N/A
N/A
Revenue
N/A
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
51.64
52 Week Low
$6.43
$4.52
52 Week High
$7.20
$7.82

Technical Indicators

Market Signals
Indicator
PNI
ICCC
Relative Strength Index (RSI) 49.96 67.39
Support Level $6.88 $5.78
Resistance Level $7.02 N/A
Average True Range (ATR) 0.11 0.30
MACD 0.02 0.13
Stochastic Oscillator 67.44 81.88

Price Performance

Historical Comparison
PNI
ICCC

About PNI Pimco New York Municipal Income Fund II of Beneficial Interest

PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: